Suppr超能文献

[重型再生障碍性贫血异基因造血干细胞移植后移植物功能不良的危险因素分析]

[Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].

作者信息

Shi C Y, Mamal Z H, Liu X X, Wu L H, Xia D N, Nie Y R, Lai F Q, Duan H W, Xiao Z J, Jiang Y H, Li Y, Xiao Yang

机构信息

Department of Hematology, General Hospital of Guangzhou Military Command of PLA, Southern Medical University, Guangzhou 510015, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):761-766. doi: 10.3760/cma.j.issn.0253-2727.2017.09.006.

Abstract

To investigate the risk factors of poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia (SAA) . Clinical data from 111 SAA patients who received allo-HSCT were analyzed retrospectively. Factors including age, gender, interval to transplantation, the level of serum ferritin before transplantation were analyzed by Cox multivariate regression analysis. Among the 111 patients who underwent allo-HSCT, 16 developed PGF (14.4%) . Multivariate analysis showed donor type (=2.656, 95% 1.204-5.858, = 0.016) and the level of serum ferritin before tansplantation (=3.170, 95% 1.400-7.180, =0.006) were significant risk factors for PGF. Unrelated donor transplantation and the high level of serum ferritin before transplantation are risk factors for PGF.

摘要

探讨重型再生障碍性贫血(SAA)患者接受异基因造血干细胞移植(allo-HSCT)后移植功能不良(PGF)的危险因素。回顾性分析111例接受allo-HSCT的SAA患者的临床资料。采用Cox多因素回归分析年龄、性别、移植间隔时间、移植前血清铁蛋白水平等因素。在111例行allo-HSCT的患者中,16例发生PGF(14.4%)。多因素分析显示供者类型(=2.656,95%可信区间1.204-5.858,=0.016)和移植前血清铁蛋白水平(=3.170,95%可信区间1.400-7.180,=0.006)是PGF的显著危险因素。无关供者移植和移植前血清铁蛋白水平高是PGF的危险因素。

相似文献

1
[Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].
Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):761-766. doi: 10.3760/cma.j.issn.0253-2727.2017.09.006.
4
Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.
Int J Med Sci. 2014 Apr 30;11(6):652-7. doi: 10.7150/ijms.6337. eCollection 2014.
9
[Outcome analysis of allogeneic hematopoietic stem cell transplantation for 41 patients with severe aplastic anemia].
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):661-5. doi: 10.3760/cma.j.issn.0253-2727.2016.08.006.

本文引用的文献

1
Hematopoietic stem cell transplantation for acquired aplastic anemia.
Curr Opin Hematol. 2016 Nov;23(6):495-500. doi: 10.1097/MOH.0000000000000281.
2
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.
Int J Hematol. 2016 Aug;104(2):168-74. doi: 10.1007/s12185-016-2037-8. Epub 2016 Jun 8.
3
Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.
Bone Marrow Transplant. 2016 Sep;51(9):1223-7. doi: 10.1038/bmt.2016.98. Epub 2016 Apr 18.
4
Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia.
Leuk Lymphoma. 2016;57(4):965-8. doi: 10.3109/10428194.2015.1085530. Epub 2015 Dec 23.
6
Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.
Int J Med Sci. 2014 Apr 30;11(6):652-7. doi: 10.7150/ijms.6337. eCollection 2014.
8
Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.
Bone Marrow Transplant. 2014 Apr;49(4):585-7. doi: 10.1038/bmt.2013.213. Epub 2014 Jan 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验